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Conclusions: Here we describe a novel, hitherto largely 
neglected mode of action exhibited by Paclitaxel. This effect 
potentially constitutes for both, Paclitaxel's cytostatic – as 
well as radiosensitizing propensity as revealed by our data 
and a recent report by Zasadil et al. (2014). Moreover, we 
identify TPX2, a potential stratification marker not only for 
combined-modality approaches involving Paclitaxel and 
radiotherapy but for Paclitaxel-based treatment regimens. 
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Purpose/Objective: Anti-Epidermal Growth Factor Receptor 
(EGFR) drugs include monoclonal antibodies and tyrosine 
kinase inhibitors (TKIs). We previously showed that gefitinib 
(an EGFR TKI) reduced the proliferating capacity of surviving 
cells after radiotherapy (RT) combined with 5-fluorouracil 
(Palumbo I et al. Int J Colorectal Dis 2014). The aim of this 
study was to compare the effect of ADZ8931 (a novel 
equipotent EGFR, HER2 and HER3 TKI), alone or combined 
with RT, with cetuximab (an anti EGFR monoclonal antibody) 
and gefitinib in the LoVo colorectal cancer cell line with a 
mild EGFR and a low ERBB2 and ERBB3 expression. 
Materials and Methods: LoVo cells were treated with 0.8 mM 
cetuximab, gefitinib and AZD8931 (alone for 5 consecutive 
days), with fractionated RT (2 Gy daily for 3 consecutive 
days), or with drugs in combination with RT (starting drugs 
administration 48 h before RT and continuing it for additional 
3 consecutive days, for a total of 5 days). After treatments, 
cell cycle and apoptosis were evaluated by cytofluorimetric 
analysis, and the clonogenic capacity by colony forming unit 
assay (counting and measuring colonies with ImageJ 
software). Results were evaluated 24h after the end of each 
treatment.  
Results: Our preliminary results showed that all drugs alone 
slightly increased the apoptotic rate and G1 and G2-M cell 
cycle phases and, accordingly, reduced the S phase. 
Interestingly, AZD 8931 induced a more marked reduction in 
the S phase (the most radioresistant cell cycle phase) 
compared with cetuximab and gefitinib. Regarding the 
clonogenic capacity, our data showed that cetuximab 
reduced colonies number and size by 25% and 50%, 
respectively, and gefitinib by 35% and 70%, respectively, 
compared to untreated cells. It is worth of notice that the 
novel AZD 8931 TKI decreased the colony-forming capacity, in 
number and size, by about 10% more than gefitinib. Exposure 
of cells to RT alone increased the apoptotic rate, enhanced 
G1 and G2-M cell cycle phases, and reduced colonies number 
and size by about 70%, compared with untreated cells. RT in 
combination with all the tested drugs potentiated the above 
reported observed changes, particularly with AZD8931.  
Conclusions: To our knowledge, this is the first study 
describing the effect of the novel equipotent EGFR, HER2 and 
HER3 TKI AZD8931 combined with RT. Our data show that 
AZD8931, most of all the other tested drugs, decreased the 
growth of LoVo cells. Since we found that AZD8931 markedly 
reduced the radioresistant S-phase is reasonable to assume 
that this drug might represent a potentially effective 
radiosensitizing agent, even in tumor cells expressing mild or 
low levels of EGFR or ERBB2, ERBB3, respectively. 
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Purpose/Objective: Peptide receptor radionuclide therapy 
(PRRT) with 90Y-DOTATOC (YD) and 177Lu-DOTATATE (LuD) has 
been shown to be effective against neuroendocrine tumors 
(NETs), with up to 35% response rate and acceptable toxicity 
profile. In the clinical history of NET patients (pts), external 
beam radiation therapy (EBRT) may be proposed, as adjuvant 
in oligometastatic disease or palliative for analgesic purpose. 
The aim of this study is to assess whether the two radiation 
therapies are compatible or arise questions about 
tolerability. 
Materials and Methods: Over 807 pts treated with PRRT 
(1997-2014) for metastatic NETs in our institute, 15% 
underwent also EBRT. Of these, 17 pts with dosimetry and 
clinical information for both therapies were selected. They 
were affected by primary tumor in pancreas (10) and ileum 
(3) NETs, intestine (1) and lung (3) carcinoids, and had 
multiple mets in liver (15), bone (9), lymph nodes (7) and 
lung (3). Fourteen pts received EBRT after PRRT, while 3 
before. In 8 cases EBRT was considered adjuvant (see figure) 
- while palliative for the remaining. Bone mets were 
irradiated by single post or ant-post fields. In case of 
oligometastases, stereotactic IMRT or RapidArc treatments 
were applied, and treatment plans optimized accounting for 
the dose received by the organs at risk (OARs) during PRRT. 
The absorbed dose on OARs and tumour (T) were assessed 
and toxicity explored (CTCAE v4 criteria). For PRRT, kidneys 
(K) and red marrow (RM) were the OARs; dose to the liver (L) 
was also evaluated. For EBRT the OARs depended on the T 
site. 
